TNF and Behcet disease: Among these agents, adalimumab is a recombinant, fully human IgG1 monoclonal antibody that specifically binds to tumor necrosis factor (TNF)-ɑ which showed durable long-term efficacy and safety in BD although there have been a few studies for intesitinal BD [16, 17].